Intas Pharma appoints Udit Sakhuja as Senior General Manager - Global New Product Launch

Published On 2025-07-02 07:10 GMT   |   Update On 2025-07-02 07:26 GMT
Advertisement

Ahmedabad: Intas Pharma has announced the appointment of Udit Sakhuja as Senior General Manager - Global New Product Launch. The company made the announcement via an official LinkedIn post, welcoming Sakhuja to its leadership team.

"We are delighted to welcome, Udit Sakhuja to Intas Pharmaceuticals as Senior General Manager – Global New Product Launch," the company stated. "Udit brings with him over a decade of rich experience, with deep expertise in launching new products and managing them end-to-end — from gathering market insights and driving strategic planning to developing roadmaps and ensuring seamless execution."
"Thrilled to drive new product journeys at Intas -with precision, passion, and a purpose to deliver value," Udit Sakhuja said.

With more than a decade of industry experience, Sakhuja joins Intas from Dr. Reddy’s Laboratories, where he served for over four years. Prior to that, he worked at Zydus Cadila as Deputy General Manager of Marketing for five years. His career also includes roles at Quest Diagnostics, Roche Products India Ltd., and Hoffmann-La Roche, as well as experience with the Department of Sustainability and Environment in Victoria, Australia.

Sakhuja holds an MBA in Marketing from Deakin University.

Read also: Intas appoints Ex-Dr Reddy's executive Rambabu Ogirala as Associate Vice President - Manufacturing Finance

Intas is a vertically integrated global pharmaceutical formulation development, manufacturing, and marketing company. Intas has set up a network of subsidiaries, under the umbrella name of Accord Healthcare to operate in global markets. Over the years, Intas has grown both organically and via acquisition, expanding its product portfolio and operations year on year. It is currently present in more than 85 countries worldwide. Intas is currently investing in a higher barrier to entry developments such as Biosimilar and New Chemical Entities.

Read also: Intas Gets CDSCO Panel Nod to Conduct Phase III Trial of Semaglutide Injection for Weight Management

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News